The British journal of dermatology
-
Randomized Controlled Trial Multicenter Study Clinical Trial
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
In previous studies, etanercept significantly improved plaque psoriasis and was well tolerated. ⋯ Etanercept provided clinically meaningful benefit to patients with chronic plaque psoriasis, with no apparent decrease in efficacy after dose reduction.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial.
There is a need for safe and effective alternative treatments for patients with moderate to severe psoriasis. ⋯ Oral pimecrolimus produces a dose-dependent reduction in psoriasis severity, with doses of 20 mg and 30 mg b.d. being the most effective and well tolerated.
-
Increased blood flow occurs in plaques of psoriasis, and an increase in blood flow has been shown to occur in uninvolved skin adjacent to the active edge. ⋯ Vascular perfusion is increased within plaques of psoriasis compared with adjacent and nonadjacent uninvolved skin. The results suggest an area of increased perfusion in skin adjacent to plaques, when compared with nonadjacent skin, for both deeper (large) and superficial (small) vessels (imaged by 633 and 532 nm, respectively). We believe that this dual wavelength tool may be a suitable and useful way of assessing pathophysiology and treatment response in psoriasis.
-
Letter Review Case Reports
Nicorandil-associated perianal ulceration with prominent elastophagocytosis and flexural ulceration.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
Psoriasis is a chronic disease that significantly diminishes the health-related quality of life (HRQOL). Infliximab is a chimeric, tumour necrosis factor alpha monoclonal antibody that has been shown to improve the signs and symptoms of plaque psoriasis. ⋯ Infliximab induction therapy resulted in significant improvement in HRQOL in patients with severe psoriasis.